Change in the incidence of Parkinson’s disease in a large UK primary care database

Abstract

Parkinson’s disease (PD) has the fastest rising prevalence of all neurodegenerative diseases worldwide. However, it is unclear whether its incidence has increased after accounting for age and changes in diagnostic patterns in the same population. We conducted a cohort study in individuals aged ≥50 years within a large UK primary care database between January 2006 and December 2016. To account for possible changes in diagnostic patterns, we calculated the incidence of PD using four case definitions with different stringency derived from the combination of PD diagnosis, symptoms, and treatment. Using the broadest case definition, the incidence rate (IR) per 100,000 person years at risk (PYAR) was 149 (95% CI 143.3–155.4) in 2006 and 144 (95% CI 136.9–150.7) in 2016. In conclusion, the incidence of PD in the UK remained stable between 2006 and 2016, when accounting for age and diagnostic patterns, suggesting no major change in underlying risk factors for PD during this time period in the UK.

Comparative effect of metformin versus sulfonylureas with dementia and Parkinson’s disease risk in US patients over 50 with type 2 diabetes mellitus

“…Second, dementia and PD tend to be underdiagnosed and under-recorded,32 44 which may lead to measurement errors in our outcomes and would tend to lead associations towards the null. We used both diagnosis and prescription records to define our outcomes which could lead to misclassification due to the off-label use of certain medications 45 46.…”

Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease

“…It has been ranked second neurodegenerative disorders worldwide just after Alzheimer's disease (AD) (1). Since its description over 200 years ago by James Parkinson, PD has shown the fastest rising prevalence of all neurodegenerative diseases worldwide (2,3). As reported in the Global Burden of Disease Study 2016, the prevalence and incidence of PD are observed in 1-2% of the population aged >60 years, which have not changed significantly in industrialized countries including the United States and UK, between 1990 and 2016 (2,3).…”

“…Since its description over 200 years ago by James Parkinson, PD has shown the fastest rising prevalence of all neurodegenerative diseases worldwide (2,3). As reported in the Global Burden of Disease Study 2016, the prevalence and incidence of PD are observed in 1-2% of the population aged >60 years, which have not changed significantly in industrialized countries including the United States and UK, between 1990 and 2016 (2,3). However, the global burden of PD has more than doubled to over 6 million as a result of increasing numbers of older people (4,5), with potential contributions from environmental factors and longer disease duration.…”

Comparative Effect of Metformin versus Sulfonylureas with Dementia and Parkinson's Disease Risk in US patients over 50 with Type 2 Diabetes Mellitus

“…Secondly, dementia and PD tend to be under-diagnosed and under-recorded [32,44], which may lead to measurement errors in our outcomes and would tend to lead associations towards the null. We used both diagnosis and prescription records to define our outcomes which could lead to misclassification due to the off-label use of certain medications [45,46].…”